News Abbott Laboratories Deutsche Boerse AG

Stocks

ABL0

CA0028221046

Medical Equipment, Supplies & Distribution

Market Closed - Deutsche Boerse AG 09:45:03 2026-10-30 EDT			5-day change	1st Jan Change
11.80 ^EUR	+3.51%		+4.42%	-11.94%

10-29	Perrigo to sell infant formula business to MeridianMade for up to $175 million	RE
10-29	Perrigo to sell infant formula business to MeridianMade for up to $175 million	RE

All News

Mentions Relevance

10-29	Abbott Laboratories Starts Trial for Device to Treat Mitral Heart Valve Disease	MT
10-29	Abbott Initiates Pivotal Trial for Cephea Mitral Valve System	CI
10-29	Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease	PR
10-28	Abbott Laboratories : receives FDA approval for first and only device in the U.S. to treat leaks after heart valve replacement without additional surgery	PU
10-27	Abbott Receives FDA Approval For Amplatzer Paraclose PVL Occluder	CI
10-27	Abbott Laboratories Shares Fall After Argus Downgrade	MT
10-27	Argus Downgrades Abbott Laboratories to Hold From Buy	MT
10-26	Abbott Laboratories Launches Oncodetect Molecular Residual Disease Test	MT
10-26	Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment	PR
10-26	Abbott Launches Whole-Genome Sequencing Oncodetect Molecular Residual Disease Test To Detect Traces Of Cancer During And After Treatment	CI
10-23	Abbott Presents New Esmo Data Showing 30-Percent Absolute Improvement in Sensitivity with the Whole-Genome Sequencing Oncodetect Test in Colorectal Cancer	CI
10-23	Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer	PR
10-22	Abbott Laboratories' Q3 Somewhat a 'Mixed Bag' With Softened Outlook, Nutrition Spinoff, Oppenheimer Says	MT
10-22	Abbott Laboratories' 2026 Guidance Cut Driven by Diabetes, Electrophysiology Portfolio, RBC Says	MT
10-22	Jefferies & Co Adjusts Abbott Laboratories Price Target to $130 From $135	MT
10-22	RBC Trims Price Target on Abbott Laboratories to $125 From $130, Keeps Outperform Rating	MT
10-22	Leerink Partners Adjusts Price Target on Abbott Laboratories to $106 From $109	MT
10-22	BTIG Adjusts Price Target on Abbott Laboratories to $125 From $134	MT
10-22	Wells Fargo Adjusts Price Target on Abbott Laboratories to $119 From $112	MT
10-22	JPMorgan Adjusts Price Target on Abbott Laboratories to $118 From $120	MT
10-22	TD Cowen Adjusts Price Target on Abbott Laboratories to $118 From $135	MT
10-21	Abbott Laboratories, Q3 2026 Earnings Call, Oct 21, 2026
10-21	Abbott to Carve Out Nutrition Business Into Independent Company -- 3rd Update	DJ
10-21	Abbott Laboratories Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
10-21	Abbott Announces Its Intention to Separate Its Nutrition Business into an Independent Publicly Traded Company	CI